Skip to main content
Syros partners with Incyte on rare bone marrow disorder drug studies
1/12/2018

Syros Pharmaceuticals and Incyte agreed to work together on the development of potential drugs to treat patients with myeloproliferative neoplasms. Under the terms of the deal, Syros will receive $20 million upfront and Incyte will have the option to obtain exclusive rights for therapies modulating up to seven validated targets discovered during the collaboration.

Full Story: